Indacaterol: Asthma therapy treatment of COPD β2- adrenoceptor agonist

Drugs of the Future

Volumn 30, Issue 12, 2005, Pages 1219-1224

  Davies, S L ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXY 5 [1 HYDROXY 2 [N [2 (4 METHOXYPHENYL) 1 METHYLETHYL]AMINO]ETHYL]CARBOSTYRIL; ARFORMOTEROL TARTRATE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARMOTEROL; FORMOTEROL; GLUCOSE; GSK 159797; GSK 159802; GSK 597901; GSK 642444; GSK 678007; INDACATEROL; PLACEBO; POTASSIUM; QAB 149; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG HALF LIFE; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; METERED DOSE INHALER; MORBIDITY; NONHUMAN; PREVALENCE;

EID: 33645125785     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.12.955084     Document Type: Article

References (30)

1. 2-Adrenoceptor agonists. EP 1183240, JP 2003501417, US 6878721, WO 2000075114.
2. Beeley, L.J., Dean, D.K. (GlaxoSmithKline plc). Heterocyclic ethanolamine derivatives with beta-adrenoreceptor agonistic activity. EP 0750617, US 5750701, WO 1995025104.
3. Lohse, O., Vogel, C. (Novartis AG; Novartis Pharma GmbH). Process for preparing 5-[(R)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy- (1H)-quinolin-2-one salt, useful as an adrenoceptor agonist. CA 2517033, EP 1599450, WO 2004076422.
4. Prous Science Drug R&D Backgrounders: Asthma (online publication). Updated November 3, 2005.
5. Prous Science Drug R&D Backgrounders: Chronic Obstructive Pulmonary Disease (Chronic Bronchitis and Emphysema) (online publication). Updated November 3, 2005.
6. Doherty, D.E. The pathophysiology of airway dysfunction. Am J Med 2004, 117(Suppl. 12A): 11S-23S.
7. Skrepnek, G.H., Skrepnek, S.V. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care 2004, 10(5, Suppl.): S129-38.
8. Mannino, D.M., Homa, D.M., Akinbami, L.J., Ford, E.S., Redd, S.C. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir Care 2002, 47: 1184-99.
9. Skrepnek, G.H., Skrepnek, S.V. An assessment of therapeutic regimens in the treatment of acute exacerbations in chronic obstructive pulmonary disease and asthma. Am J Manag Care 2004, 10(5, Suppl.): S139-52.
10. Sears, M.R., Lotvall, J. Past, present and future - β2-adrenoceptor agonists in asthma management. Respir Med 2005, 99: 152-70.
11. Novartis reports phase III data and update of R&D pipeline. DailyDrugNews.com (Daily Essentials) Sept 22, 2005.
12. Lewis, C. A., Jordan, L., Farr, C., Fozard, R. Indacaterol: Preclinical evidence for an improved safety profile vs LABAs. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1401.
13. Lewis, C. A., Jordan, L., Farr, D.C., Fozard, J.R. QAB149: Preclinical evidence for an improved safety profile vs LABAs. Proc Am Thorac Soc 2005, 2(Abstracts Issue): A355.
14. 2-agonist, demonstrates a long duration of action and fast onset in vitro and in vivo in the guinea pig. Proc Am Thorac Soc 2005, 2(Abstracts Issue): A355.
15. 2-agonist, demonstrates a long duration of action and fast onset in vitro and in vivo in the guinea pig. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P835.
16. 2-agonist, on isolated human bronchus. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1399.
17. 2- agonist, on the isolated human bronchus. Proc Am Thorac Soc 2005, 2(Abstracts Issue): A356.
18. 2- agonist, on the isolated human bronchus. Proc Am Thorac Soc 2005, 2(Abstracts Issue): A356.
19. 2-agonist, on isolated human bronchus. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1398.
20. Battram, H., Mok, J., Lewis, A. Once-daily administration of indacaterol does not induce tachyphylaxis in vivo. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1400.
21. Battram, H., Mok, J, Lewis, C.A. Once-daily administration of QAB149 does not induce tachyphylaxis in vivo. Proc Am Thorac Soc 2005, 2(Abstracts Issue): A356.
22. 2-agonist, in moderate to severe COPD. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1965.
23. 2 agonist, is effective and well tolerated on multiple dosing in patients with mild to moderate COPD. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1920.
24. 2-agonist, is well tolerated in patients with mild asthma. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1727.
25. 2-agonist, in patients with mild asthma. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1726.
26. 2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: A multiple-dose, dose-ranging study. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1729.
27. 2- agonist, in patients with stable asthma. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1728.
28. 2-agonist, in patients with stable asthma. Proc Am Thorac Soc 2005, 2(Abstracts Issue): A356.
29. 2-agonist with 24-hour bronchodilation. 15th Annu Congr Eur Respir Soc (ERS) (Sept 17-21, Copenhagen) 2005, Abst P1725.
30. 2-agonist with 24-hour bronchodilation. Proc Am Thorac Soc 2005, 2(Abstracts Issue): A356.